text
"['\nIX. 계열회사 등에 관한 사항\n가. 계열회사 출자\xa0현황기업집단의 명칭: 셀트리온(주)셀트리온은「독점규제 및 공정거래에 관한 법률」상 셀트리온그룹에 속한 계열회사로서 2021년 1분기말 현재 계열회사 현황은 아래와 같습니다. \n(기준일: 2021년 03월 31일)\n(단위 : %)\n계열회사명\n사업자등록번호\n투\xa0 자\xa0 자\n서 정 진\n㈜셀트리온\n㈜셀트리온홀딩스\n㈜셀트리온헬스케어\n㈜셀트리온헬스케어홀딩스\n㈜셀트리온스킨큐어\n㈜셀트리온제약\n계\n㈜셀트리온\n133-81-23603\n-\n-\n20.02\n-\n-\n2.12\n-\n\xa0 \xa0\xa0 22.14\n㈜셀트리온홀딩스\n131-86-24858\n\xa0 \xa0\xa0 95.51\n\xa0-\n-\n\xa0-\n-\n\xa0-\n\xa0-\n\xa0 \xa0\xa0 95.51\n㈜셀트리온헬스케어\n123-81-53473\n\xa0 \xa0\xa0 11.20\n\xa0-\n\xa0-\n\xa0-\n24.30\n1.39\n\xa0-\n\xa0 \xa0\xa0 36.88\n㈜셀트리온헬스케어홀딩스\n480-86-01873\n\xa0\xa0 100.00\n-\n-\n-\n-\n-\n-\n\xa0\xa0 100.00\n㈜셀트리온스킨큐어\n105-86-13560\n\xa0 \xa0\xa0 70.23\n\xa0-\n\xa0-\n\xa0-\n-\n\xa0-\n\xa0-\n\xa0 \xa0\xa0 70.23\n㈜셀트리온제약\n214-86-71641\n\xa0-\n54.96\n-\n\xa0-\n-\n\xa0-\n\xa0-\n\xa0 \xa0\xa0 54.96\n㈜셀트리온엔터테인먼트\n107-87-63802\n\xa0-\n\xa0-\n100.00\n\xa0-\n-\n\xa0-\n\xa0-\n\xa0\xa0 100.00\n㈜셀트리온 충북대 바이오메딕스\n417-87-01299\n-\n50.00\n-\n-\n-\n-\n-\n\xa0 \xa0\xa0 50.00\n㈜셀트리온 충북대 코스메틱스\n338-88-01033\n-\n-\n-\n-\n-\n50.00\n-\n\xa0 \xa0\xa0 50.00\n나. 회사와 계열회사간 임원 겸직 현황\n성명\n계열회사 겸직현황\n회사명\n직위\n상근여부\n서진석\n셀트리온홀딩스\n사내이사\n상근\n셀트리온제약\n사내이사\n상근\n셀트리온헬스케어홀딩스\n사내이사\n상근\n셀트리온스킨큐어\n기타비상무이사\n비상근\n셀트리온엔터테인먼트\n기타비상무이사\n비상근\n다. 타법인출자 현황\n(기준일 :\xa0\n2021년 03월 31일\n)\n(단위 : 천원, 주, %)\n법인명\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\nA&G Pharmaceutical, Inc (비상장)\n2006.07.14\n신약개발투자\n2,676,548\xa0\n987,889\n16.51\n116,349\n-\n-\n-\n987,889\n16.51\n116,349\n2,912,601\n1,062,859\n셀트리온 유럽 (비상장)\n2009.07.21\n유럽임상관련투자\n2\xa0\n1\n100.00\n2\n-\n-\n-\n1\n100.00\n2\n2\n-\n바이오톡스텍 (상장)\n2009.07.28\n투자수익\n2,025,000\xa0\n1,631,134\n11.15\n24,793,236\n-\n-\n-8,155,670\n1,631,134\n11.15\n16,637,566\n63,705,372\n2,016,035\n보스톤 인큐베이션투자조합 (비상장)\n2009.11.27\n투자수익\n2,500,000\xa0\n11\n25.00\n83,007\n-\n-\n-\n11\n25.00\n83,007\n336,194\n-2,342\n제이티비씨 (비상장)\n2017.09.20\n투자수익\n500,000\xa0\n100,000\n0.09\n33,940\n-\n-\n44,469\n100,000\n0.09\n78,409\n401,083,935\n-25,497,001\n프리미어 글로벌이노베이션 1호 (비상장)\n2017.06.15\n유망 바이오 벤처기업투자\n250,000\xa0\n3,445\n6.67\n3,444,767\n-593\n-593,333\n-\n2,852\n6.67\n2,851,434\n99,189,160\n24,256,551\n프리미어 글로벌이노베이션 2호 (비상장)\n2020.11.05\n유망 바이오 벤처기업투자\n250,000\xa0\n250\n5.56\n250,000\n500\n500,000\n-\n750\n5.56\n750,000\n4,500,138\n-188,067\n매일방송 (비상장)\n2011.03.17\n투자수익\n1,000,000\xa0\n250,981\n0.48\n1,475,167\n-\n-\n-\n250,981\n0.48\n1,475,167\n393,311,270\n1,890,589\n뉴스1 (비상장)\n2011.06.09\n투자수익\n500,000\xa0\n60,000\n5.00\n300,000\n-\n-\n-\n60,000\n5.00\n300,000\n22,282,973\n2,335,332\n셀트리온제약 (상장)\n2013.04.23\n경영참가 등\n50,057,259\xa0\n19,682,190\n54.96\n255,342,176\n393,643\n-\n-\n20,075,833\n54.96\n255,342,176\n548,074,598\n20,936,032\n2014 성장사다리-IMM벤처펀드 (비상장)\n2014.08.11\n투자수익\n2,000,000\xa0\n2,500\n20.00\n1,683,844\n-\n-\n-\n2,500\n20.00\n1,683,844\n9,083,445\n-1,724,638\n미래에셋셀트리온신성장투자조합 1호\xa0 (비상장)\n2017.03.31\n유망 바이오 벤처기업투자\n6,250,000\xa0\n425\n50.00\n42,500,000\n-25\n-2,500,000\n-\n400\n50.00\n40,000,000\n92,202,238\n1,646,447\nCelltrion Global Safety Data Center (비상장)\n2018.05.23\n글로벌 의약품 안전성 데이터 관리\n1,106,930\xa0\n580,563\n99.99\n1,204,581\n-\n-\n-\n580,563\n99.99\n1,204,581\n1,896,634\n200,712\nCelltrion USA, Inc.(비상장)\n2018.07.24\n케미컬의약품 판매유통망 구축\n38,973\xa0\n3,050\n100.00\n6,951,601\n-\n-\n-\n3,050\n100.00\n6,951,601\n12,816,032\n-8,632,880\nCelltrion Group Hongkong ltd (비상장)\n2019.04.01\n바이오의약품 중국사업\n5,680,500\xa0\n7,023,270\n70.00\n8,086,365\n-\n-\n-\n7,023,270\n70.00\n8,086,365\n29,554,539\n-547,241\n셀트리온충북대바이오메딕스 (비상장)\n2018.07.18\n신약 및 원료의약품 연구개발\n100,000\xa0\n20,000\n50.00\n100,000\n-\n-\n-\n20,000\n50.00\n100,000\n152,990\n-15,974\nCelltrion Asia Pacific PTE (비상장)\n2020.11.23\n케미컬의약품 판매 및 연구개발\n315,987,120\xa0\n283,600,000\n100.00\n315,987,120\n-\n-\n-\n283,600,000\n100.00\n315,987,120\n325,408,677\n-3,294,286\n합 계\n313,945,709\n-\n662,352,155\n393,525\n-2,593,333\n-8,111,201\n314,339,234\n-\n651,647,621\n2,006,510,798\n14,442,128\n']"
